OCDC

The Ocular Coil Drug Delivery Comfort Trial

The administration of drugs to the eye is normally done by means of eye drops. For most patients this is easy to do, but there are disadvantages to this route of administration. For example, when applying eye drops only a proportion of the drops are retained in the eye leading to a low amount of drug being absorbed by the tissue. To counteract this, frequent administration with high drug concentrations is required, which can result in side effects or low levels of patient compliance. A new implant is being developed in the form of a flexible rod that is placed under the eyelid in the conjunctival fornix. This rod comprises a unique biomaterial that can deliver a drug over a period of weeks to months. This innovative way of drug administration results in better patient compliance with fewer side effects and improved delivery of drug to the front of the eye.

flag icon

Project status 2016-017 

The project had a successful start and by the beginning of 2018, OCDC is expected to have the clinical grade drug-loaded microspheres. This means that the first step for going from bench to bedside has been taken. After the microspheres are tested, the ocular coil needs to be tested as well. These results are planned to be ready in the beginning of 2019. The next step will be to evaluate the ocular coil in a large cohort of patients. These clinical evaluation studies would be working towards providing the ocular coil as medical device to the clinic.

Rudy Nuijts

Project leader

Prof. Rudy Nuijts, MD, PhD
Maastricht University Medical Center
Meet Rudy Nuijts on LinkedIn 

Project Partners

Eindhoven University of Technology, Maastricht University & University Medical Center, Eyegle BV

Chemelot InSciTe